Global Pancreatic Cancer Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Pancreatic Cancer Diagnostics Market Segmentation, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type (Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2032

Pancreatic Cancer Diagnostics Market Size

• The global pancreatic cancer diagnostics market size was valued at USD 3.00 billion in 2024 and is expected to reach USD 5.35 billion by 2032, at a CAGR of 7.50% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress within diagnostic imaging, biomarker research, and molecular testing, leading to increased digitalization and precision in healthcare settings
• Furthermore, rising demand for accurate, minimally invasive, and early detection solutions for pancreatic cancer is establishing advanced diagnostics as a critical component of modern oncology care. These converging factors are accelerating the uptake of pancreatic cancer diagnostic solutions, thereby significantly boosting the industry's growth in the coming years

Pancreatic Cancer Diagnostics Market Analysis

• Pancreatic cancer diagnostics play a vital role in improving survival rates, as the disease is often detected at advanced stages. Advances in imaging, biomarkers, and molecular diagnostics are accelerating the market’s growth
• The rising demand is driven by increasing global incidence of pancreatic cancer, growing awareness about the benefits of early detection, higher healthcare spending, and the adoption of innovative, non-invasive diagnostic technologies
• North America dominated the pancreatic cancer diagnostics market, accounting for 41.8% of revenue in 2024, supported by advanced healthcare infrastructure, early adoption of novel diagnostics, strong R&D activities, and favorable reimbursement policies. The U.S. remains the largest contributor within the region
• Asia-Pacific is expected to record the fastest growth during the forecast period in the pancreatic cancer diagnostics market, driven by rapid urbanization, expanding healthcare access, rising disposable incomes, and the growing prevalence of pancreatic cancer in emerging economies such as China and India
• Exocrine tumors dominated the pancreatic cancer diagnostics market with a market share of 86.2% in 2024, since pancreatic ductal adenocarcinoma (PDAC), a type of exocrine tumor, makes up the overwhelming majority of diagnosed cases. This high prevalence directly translates into increased demand for a wide array of diagnostic methods including imaging, biopsy, and molecular testing

Report Scope and Pancreatic Cancer Diagnostics Market Segmentation     

Pancreatic Cancer Diagnostics Market Trends

Enhanced Convenience Through Advanced Pancreatic Cancer Diagnostics

• A significant and accelerating trend in the global pancreatic cancer diagnostics market is the adoption of more advanced, accurate, and less invasive diagnostic technologies. This shift is significantly enhancing patient convenience, early detection, and overall disease management outcomes

  • For instance, liquid biopsy-based tests are increasingly being adopted due to their ability to detect cancer biomarkers in blood samples. Unlike traditional tissue biopsies, these methods are minimally invasive and can be repeated frequently, improving patient comfort and enabling real-time monitoring of disease progression

• The integration of next-generation sequencing (NGS) into pancreatic cancer diagnostics enables comprehensive genomic profiling, which supports precision medicine approaches. This helps clinicians identify specific mutations and tailor targeted therapies, thereby optimizing treatment strategies
• Advances in imaging technologies such as endoscopic ultrasound (EUS), MRI, and PET-CT scans are improving diagnostic accuracy, allowing earlier detection and better differentiation between benign and malignant pancreatic lesions
• The seamless connection between diagnostic modalities and digital pathology platforms facilitates centralized data analysis and remote consultations. This enables multidisciplinary teams to collaborate more effectively and deliver faster, evidence-based decisions for patient care
• This trend toward more intelligent, precise, and integrated diagnostic systems is fundamentally reshaping expectations in oncology. Consequently, companies such as Roche Diagnostics, Thermo Fisher Scientific, and Qiagen are actively developing innovative biomarker-based tests and molecular diagnostics tailored for pancreatic cancer detection and monitoring
• The demand for accurate, rapid, and patient-friendly diagnostic solutions is growing rapidly across both clinical and research settings, as healthcare providers and patients increasingly prioritize early detection, personalized treatment, and improved survival outcomes

Pancreatic Cancer Diagnostics Market Dynamics

Driver

Growing Need for Early Detection and Technological Advancements

• The rising incidence of pancreatic cancer worldwide, coupled with its high mortality rate due to late-stage diagnosis, is a significant driver for the increased demand for advanced diagnostic solutions

  • For instance, in March 2024, researchers introduced innovative liquid biopsy platforms capable of detecting circulating tumor DNA at very early stages, offering the potential to transform clinical outcomes for pancreatic cancer patients. Such technological progress and strategic initiatives by leading players are expected to accelerate the growth of the pancreatic cancer diagnostics industry in the forecast period

• As awareness about the importance of early detection grows, healthcare providers are prioritizing accurate, minimally invasive, and efficient testing methods. This has driven the adoption of advanced diagnostic modalities such as molecular profiling, next-generation sequencing, and AI-assisted imaging tools
• Furthermore, increasing investments in precision medicine, biomarker research, and integrated diagnostic approaches are making these solutions an indispensable component of modern oncology care. The demand for such innovations is further strengthened by government initiatives, clinical trials, and collaborations between biotech firms and healthcare institutions
• The convergence of these factors is significantly boosting the adoption of pancreatic cancer diagnostic solutions, thereby driving strong market growth in the coming years

Restraint/Challenge

High Costs and Limited Accessibility in Developing Regions

• Despite advancements, the relatively high costs of advanced pancreatic cancer diagnostic tests, such as genomic sequencing and molecular imaging, pose a significant challenge to wider adoption
• These costs often act as a barrier in low- and middle-income countries where healthcare budgets are constrained and access to specialized facilities is limited

  • For instance, while next-generation sequencing has shown immense promise in identifying genetic mutations linked to pancreatic cancer, the infrastructure and skilled expertise required for such testing remain unavailable in many regions

• This limits the widespread adoption of cutting-edge diagnostics and contributes to disparities in patient outcomes
• Another concern is the lack of standardized screening protocols for early-stage pancreatic cancer detection. Since symptoms are often absent until advanced stages, many patients are diagnosed too late, highlighting an urgent need for more accessible and affordable screening programs
• Addressing these challenges through cost-reduction strategies, expanding insurance coverage, increasing government funding, and investing in portable or point-of-care diagnostic tools will be essential for ensuring equitable access
• Companies focusing on developing affordable diagnostic solutions and partnerships with public health organizations are likely to play a key role in overcoming these barriers

Pancreatic Cancer Diagnostics Market Scope

The pancreatic cancer diagnostics market is segmented on the basis of test type, cancer stage, tumor type, product, technology, application, end user, and distribution channel.

• By Test Type

On the basis of test type, the pancreatic cancer diagnostics market is segmented into imaging test, biopsy, blood test, genomic test, and others. The imaging test segment dominated the largest market revenue share of 39.5% in 2024, primarily because imaging plays a central role across all stages of pancreatic cancer detection, staging, and monitoring. Advanced imaging technologies such as CT scans, MRIs, PET scans, and endoscopic ultrasounds are often the first line of diagnostic evaluation when symptoms such as jaundice or abdominal pain appear. The ability of imaging tests to detect tumor size, local spread, and involvement of nearby vessels makes them indispensable for treatment planning. Furthermore, improvements in contrast agents, integration of AI algorithms for enhanced interpretation, and wider availability in both developed and emerging healthcare systems continue to strengthen their market share. Rising investments in hospital imaging infrastructure, coupled with growing demand for non-invasive diagnostic options, further amplify this dominance globally.

The genomic test segment, on the other hand, is projected to expand at the fastest CAGR of 12.5% from 2025 to 2032, as genomic profiling becomes a cornerstone of precision oncology. Genomic testing allows physicians to identify actionable mutations such as BRCA1/2, KRAS, and PALB2, which are critical for determining eligibility for targeted therapies or immunotherapy. This test type has gained traction because it not only supports accurate diagnosis but also guides long-term personalized treatment approaches, improving patient survival chances. The growing adoption of next-generation sequencing (NGS), coupled with declining costs of genetic testing, is making genomic diagnostics more accessible across hospitals and diagnostic laboratories. In addition, increased focus from pharmaceutical companies on developing companion diagnostics, and regulatory bodies encouraging biomarker-driven trials, are accelerating the demand for genomic tests, especially in North America and Europe.

• By Cancer Stage

On the basis of cancer stage, the pancreatic cancer diagnostics market is segmented into Stage 0, Stage I, Stage II, Stage III, and Stage IV. The Stage II segment dominated the market with the largest share of 32.0% in 2024, as this is the stage where most patients are diagnosed due to the appearance of more evident symptoms. At Stage II, pancreatic cancer has typically spread to nearby lymph nodes but may still be surgically resectable, making diagnostic tests essential for evaluating operability and planning therapeutic approaches. Imaging modalities, combined with tissue biopsy and biomarker evaluations, are routinely employed at this stage to assess disease extent. Growing awareness among patients, broader use of health screening programs, and advancements in imaging accuracy have increased detection rates at this stage. Furthermore, healthcare providers emphasize aggressive diagnostic testing at Stage II because early intervention can significantly extend survival outcomes compared to late-stage detection.

Stage 0, however, is projected to record the fastest CAGR of 13.0% from 2025 to 2032, as global healthcare systems place stronger emphasis on preventive oncology and early-stage cancer detection. Although Stage 0 cases are rare and often identified incidentally during genetic screenings or surveillance of high-risk groups, advances in biomarker research and liquid biopsy are making earlier detection increasingly possible. Growing use of genetic counseling for families with hereditary pancreatic cancer syndromes, combined with government-funded preventive programs, is helping to expand this segment. Early-stage detection also benefits from improved blood-based biomarker assays capable of identifying circulating tumor DNA. These innovations, along with AI-powered risk prediction tools, make Stage 0 detection a promising and rapidly evolving area within the diagnostics landscape.

• By Tumor Type

On the basis of tumor type, the pancreatic cancer diagnostics market is segmented into exocrine tumors and neuroendocrine tumors. Exocrine tumors accounted for the largest market share of 86.2% in 2024, since pancreatic ductal adenocarcinoma (PDAC), a type of exocrine tumor, makes up the overwhelming majority of diagnosed cases. This high prevalence directly translates into increased demand for a wide array of diagnostic methods including imaging, biopsy, and molecular testing. Because exocrine tumors typically progress aggressively and are often diagnosed at advanced stages, there is heavy reliance on multi-modal diagnostic approaches to confirm the disease, stage it accurately, and evaluate treatment options. Hospitals and cancer centers worldwide allocate substantial resources for exocrine tumor diagnostics due to their high incidence, poor survival rates, and urgent need for comprehensive testing. In addition, ongoing clinical trials, wider insurance coverage for imaging and biopsy procedures, and strong funding for pancreatic cancer research ensure that exocrine tumors will remain the dominant diagnostic focus.

Neuroendocrine tumors, in contrast, are expected to grow at the fastest CAGR of 11.4% from 2025 to 2032, as rising clinical awareness and improved diagnostic modalities lead to more frequent identification of these rare cancers. Unlike exocrine tumors, neuroendocrine tumors often present more indolently, which historically led to underdiagnosis. However, modern imaging techniques such as Ga-68 DOTATATE PET/CT, combined with advances in biomarker testing, are enabling earlier and more accurate identification of these cases. Growing use of somatostatin receptor imaging and next-generation molecular assays are expanding diagnostic precision. Furthermore, pharmaceutical companies are increasingly investing in therapies for neuroendocrine tumors, which indirectly drives diagnostic demand. While still a smaller segment in terms of volume, neuroendocrine tumor diagnostics are steadily gaining importance due to better survival outcomes and rising prevalence in both developed and emerging markets.

• By Product

On the basis of product, the pancreatic cancer diagnostics market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables. Instrument-based products dominated the market with the largest share of 41.8% in 2024, owing to the widespread use of diagnostic equipment such as MRI scanners, CT scanners, PET scanners, and endoscopic ultrasound devices. These instruments form the backbone of pancreatic cancer detection, staging, and monitoring, and healthcare institutions worldwide continue to invest heavily in them. Increasing government funding for cancer diagnostic infrastructure, coupled with rising hospital budgets dedicated to oncology care, is further fueling this segment’s dominance. The ongoing integration of artificial intelligence into imaging instruments, enabling more precise detection of small lesions and metastases, has also elevated demand for advanced machines. Furthermore, the expansion of diagnostic imaging centers in emerging economies ensures steady growth for instrument-based products.

Kits and reagents, however, are projected to witness the fastest CAGR of 12.7% from 2025 to 2032, as liquid biopsy and blood-based biomarker testing gain wider clinical adoption. Diagnostic kits designed for detecting CA19-9, circulating tumor DNA, and other biomarkers are becoming increasingly important for both screening high-risk populations and monitoring treatment response. Their affordability, ease of use in laboratories, and ability to provide rapid results make them attractive for smaller diagnostic centers as well as large hospitals. In addition, partnerships between biotech firms and research organizations are accelerating the development of new assay kits that can detect multiple biomarkers simultaneously, boosting their adoption. The rising demand for minimally invasive diagnostic options, coupled with the expansion of molecular diagnostic labs globally, positions kits and reagents as one of the most promising growth categories.

• By Technology

On the basis of technology, the pancreatic cancer diagnostics market is segmented into fluorescent in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. The fluorescent in situ hybridization (FISH) segment held the largest market revenue share of 34.2% in 2024, driven by its established role in detecting chromosomal abnormalities and genetic markers linked to pancreatic cancer progression. FISH enables precise visualization of specific genetic changes in tumor samples, providing oncologists with critical information for confirming diagnoses and guiding treatment strategies. Hospitals and specialized cancer centers have long relied on FISH due to its high accuracy, making it a standard molecular diagnostic tool in oncology. Moreover, the growing demand for companion diagnostics and biomarker-driven drug development further supports the continued dominance of this technology.

The next-generation sequencing (NGS) segment is expected to witness the fastest CAGR of 14.0% from 2025 to 2032, reflecting the broader industry shift toward precision medicine. NGS allows simultaneous analysis of multiple genes and biomarkers, providing a comprehensive genetic profile of the tumor. This is particularly important for pancreatic cancer, where actionable mutations such as KRAS, BRCA, and PALB2 significantly influence treatment decisions. The declining cost of sequencing, improved turnaround times, and expanding reimbursement coverage in developed markets are driving adoption. In addition, collaborations between diagnostic companies and pharmaceutical firms to co-develop targeted therapies with NGS-based companion diagnostics are accelerating growth. The ability of NGS to guide personalized treatment regimens and improve patient survival outcomes makes it one of the most disruptive technologies in pancreatic cancer diagnostics.

• By Application

On the basis of application, the pancreatic cancer diagnostics market is segmented into hospitals, diagnostic centers, academic and research institutes, and others. The hospital segment accounted for the largest market revenue share of 45.6% in 2024, as hospitals remain the primary point of care for cancer diagnosis, treatment, and monitoring. The integration of advanced imaging modalities, surgical pathology labs, and genomic testing facilities within hospitals ensures comprehensive patient management. Hospitals also benefit from strong financial resources, government funding, and the ability to offer multidisciplinary cancer care, making them the most prominent users of diagnostic technologies. Furthermore, the rising prevalence of pancreatic cancer cases worldwide and increasing patient referrals to tertiary care hospitals strengthen this segment’s growth.

Academic and research institutes are projected to grow at the fastest CAGR of 11.8% from 2025 to 2032, as these centers play a critical role in advancing diagnostic innovation. Research organizations are at the forefront of developing novel biomarkers, liquid biopsy assays, and AI-driven diagnostic tools that can detect pancreatic cancer earlier and with greater accuracy. Increasing government grants and private funding for cancer research is fueling expansion of diagnostic studies and clinical trials. Moreover, collaborations between universities, biotech startups, and pharmaceutical companies are fostering the rapid translation of laboratory discoveries into commercially available diagnostic products. The expansion of precision medicine research programs across North America, Europe, and Asia-Pacific also highlights the increasing importance of this segment in shaping the future of pancreatic cancer diagnostics.

• By End User

On the basis of end user, the pancreatic cancer diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, cancer research centers, and others. The hospitals & clinics segment captured the largest market revenue share of 49.0% in 2024, supported by the fact that most pancreatic cancer patients initially seek care in hospitals or are referred there for advanced diagnostic evaluation. Hospitals and clinics are equipped with comprehensive diagnostic tools, from imaging systems to biopsy facilities, allowing them to provide rapid, integrated diagnostic workflows. They also benefit from government initiatives that fund cancer care infrastructure, especially in developed regions like North America and Europe. In addition, the increasing global burden of pancreatic cancer is leading to more diagnostic testing being performed in hospital settings, reinforcing their leading position in the market.

Diagnostic laboratories are projected to register the fastest CAGR of 12.2% between 2025 and 2032, as they play a pivotal role in the processing of blood tests, genomic profiling, and advanced biomarker assays. With the rising adoption of liquid biopsy and NGS technologies, specialized diagnostic labs are becoming essential partners for oncologists. Many diagnostic labs also collaborate with pharmaceutical firms to develop companion diagnostics, creating additional revenue streams. Their ability to handle large volumes of patient samples with high efficiency, combined with growing outsourcing of testing by smaller hospitals and clinics, has made diagnostic laboratories increasingly indispensable. Expanding lab networks in emerging economies, coupled with higher healthcare expenditure, further strengthens this growth trajectory.

• By Distribution Channel

On the basis of distribution channel, the pancreatic cancer diagnostics market is segmented into direct tenders, retail sales, and online sales. The direct tenders segment accounted for the largest share of 52.3% in 2024, primarily due to bulk procurement of diagnostic instruments, consumables, and kits by hospitals, diagnostic centers, and government institutions. Large-scale purchases through tenders ensure cost efficiency, timely supply, and streamlined procurement processes for healthcare providers. Governments and large hospital networks typically prefer this channel, as it guarantees compliance with regulations and provides favorable pricing structures. Direct tender agreements also foster long-term partnerships between diagnostic product manufacturers and healthcare systems, ensuring stable demand and consistent supply.

Online sales, meanwhile, are projected to expand at the fastest CAGR of 13.5% from 2025 to 2032, driven by the growing digitalization of healthcare procurement systems and the rising preference for convenient purchasing platforms. Diagnostic laboratories and smaller healthcare providers are increasingly turning to online channels for acquiring reagents, test kits, and small-scale instruments due to faster delivery options and transparent pricing. E-commerce platforms specializing in medical supplies have emerged, making it easier for diagnostic stakeholders to access a wide range of products without extensive procurement negotiations. The COVID-19 pandemic further accelerated adoption of digital procurement in healthcare, creating a lasting trend. In addition, the rising presence of global diagnostic companies on online B2B platforms ensures that even institutions in remote regions can source high-quality diagnostic products.

Pancreatic Cancer Diagnostics Market Regional Analysis

• North America dominated the pancreatic cancer diagnostics market with the largest revenue share of 41.8% in 2024, supported by advanced healthcare infrastructure, early adoption of novel diagnostics, strong R&D activities, and favorable reimbursement policies
• The region continues to lead in the integration of precision medicine and next-generation sequencing into oncology care, reflecting high awareness among both patients and healthcare professionals about the importance of early detection
• This leadership is further reinforced by significant investments in clinical research, the presence of major diagnostic companies, and government initiatives that prioritize cancer screening programs. The increasing use of AI-driven imaging and biomarker-based blood tests highlights North America’s position as a global frontrunner in pancreatic cancer diagnostics

U.S. Pancreatic Cancer Diagnostics Market Insight

The U.S. pancreatic cancer diagnostics market captured the largest revenue share within North America in 2024, primarily driven by its robust healthcare ecosystem and high demand for innovative diagnostic solutions. The country’s strong emphasis on early cancer detection, combined with widespread insurance coverage for advanced testing, is fueling adoption across hospitals, diagnostic centers, and research institutions. Rapid technological advancements, such as liquid biopsies and genomic testing, are widely implemented in clinical practice, positioning the U.S. as the most lucrative market in the region. In addition, collaborations between biotech companies and academic research centers are accelerating the introduction of novel diagnostic assays.

Europe Pancreatic Cancer Diagnostics Market Insight

The Europe pancreatic cancer diagnostics market is projected to expand at a substantial CAGR throughout the forecast period, driven by rising cancer incidence rates and increasing government support for screening programs. Growing investments in molecular diagnostics and personalized medicine are fostering adoption across the region. Furthermore, regulatory frameworks emphasizing early detection and better patient outcomes are contributing to market expansion. The availability of specialized cancer care centers and Europe’s focus on research-driven healthcare innovation are ensuring steady growth in both developed markets like Germany and the U.K. as well as emerging Eastern European economies.

U.K. Pancreatic Cancer Diagnostics Market Insight

The U.K. pancreatic cancer diagnostics market is anticipated to grow at a noteworthy CAGR during the forecast period, fueled by the government’s cancer care initiatives such as the NHS Long Term Plan, which emphasizes early diagnosis and improved survival rates. Increasing adoption of non-invasive diagnostic methods, coupled with strong academic research output and collaborations with diagnostic firms, is enhancing the country’s position in the European market. In addition, the rising patient awareness of early cancer detection and the expansion of clinical trials for biomarker validation are expected to further strengthen growth.

Germany Pancreatic Cancer Diagnostics Market Insight

The Germany pancreatic cancer diagnostics market is expected to expand at a considerable CAGR during the forecast period, supported by the country’s strong healthcare infrastructure, well-established diagnostic laboratories, and growing preference for advanced molecular testing. Germany’s emphasis on innovation and adoption of precision medicine is accelerating the uptake of liquid biopsy and next-generation sequencing for pancreatic cancer diagnostics. The country’s sustained investment in R&D and active participation in EU-wide cancer research initiatives further support market growth.

Asia-Pacific Pancreatic Cancer Diagnostics Market Insight

The Asia-Pacific pancreatic cancer diagnostics market is poised to grow at the fastest CAGR during 2025–2032, driven by rapid urbanization, expanding healthcare access, rising disposable incomes, and the growing prevalence of pancreatic cancer in emerging economies such as China and India. Increasing government investments in healthcare infrastructure, coupled with growing awareness programs and the expansion of diagnostic laboratories, are key contributors to regional growth. Moreover, the emergence of Asia-Pacific as a hub for clinical research and affordable diagnostic solutions is expected to make advanced pancreatic cancer diagnostics more accessible across a broader population base.

Japan Pancreatic Cancer Diagnostics Market Insight

The Japan pancreatic cancer diagnostics market is gaining momentum due to its technologically advanced healthcare system, rapid urbanization, and high patient awareness of early cancer detection. The country’s strong focus on innovation and integration of advanced molecular diagnostics into mainstream healthcare is accelerating market growth. Furthermore, Japan’s aging population is driving demand for early detection solutions, ensuring steady uptake of both imaging-based and biomarker-driven diagnostic methods in hospitals and research institutes.

China Pancreatic Cancer Diagnostics Market Insight

China pancreatic cancer diagnostics market accounted for the largest revenue share in Asia-Pacific in 2024, supported by its expanding middle class, rapid urbanization, and increasing healthcare investments. The country is witnessing rising adoption of molecular diagnostics and liquid biopsy techniques, supported by government initiatives such as “Healthy China 2030” which emphasize early cancer detection. Strong domestic manufacturing capabilities, coupled with international partnerships, are making advanced diagnostic solutions more affordable and widely available, further fueling market growth.

Pancreatic Cancer Diagnostics Market Share

The pancreatic cancer diagnostics industry is primarily led by well-established companies, including:

• Siemens Healthineers AG (Germany)
• Koninklijke Philips N.V. (Netherlands)
• FUJIFILM Corporation (Japan)
• GRAIL, Inc. (U.S.)
• Labcorp (U.S.)
• DiaSource (Belgium)
• Abbott (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Lee Biosolutions, Inc. (U.S.)
• MP BIOMEDICALS (U.S.)
• Setia Scientific Solution (India)
• Boditech Med Inc. (South Korea)
• AccuBioTech Co., Ltd. (China)
• Thermo Fisher Scientific (U.S.)
• Creative Biolabs (U.S.)
• Myriad Genetics, Inc. (U.S.)
• BD (U.S.)
• Canon Medical Systems Corporation (Japan)
• QIAGEN (Netherlands)
• Meridian Life Science, Inc. (U.S.)
• CTK Biotech, Inc. (U.S.)

Latest Developments in Global Pancreatic Cancer Diagnostics Market

• In October 2021, Biological Dynamics announced that its Exo-PDAC liquid biopsy test for early detection of pancreatic ductal adenocarcinoma received FDA Breakthrough Device Designation, marking a significant milestone in advancing non-invasive early detection solutions
• In November 2023, a study published in Nature Medicine introduced PANDA, a deep-learning system capable of detecting pancreatic cancer on non-contrast CT scans with high accuracy, showcasing the potential of artificial intelligence to support large-scale opportunistic screening
• In February 2024, researchers at UCLA Health developed an artificial intelligence model that identified pancreatic tumors on CT scans up to three years earlier than traditional clinical diagnosis, with an accuracy rate of nearly 87%, underlining AI’s transformative role in early detection
• In April 2024, clinical data presented at the American Association for Cancer Research (AACR) annual meeting revealed that an exosome-based liquid biopsy, when combined with CA 19-9, was able to detect 97% of stage I–II pancreatic cancers, reinforcing the promise of liquid biopsies in early-stage detection
• In May 2024, the U.S. National Cancer Institute reported findings from a large study demonstrating that a liquid biopsy blood test accurately detected early-stage pancreatic cancer, further validating the clinical potential of blood-based diagnostics
• In October 2024, GRAIL released initial results from its real-world REFLECTION study on the Galleri multi-cancer early detection test, which includes pancreatic cancer among the detected types, showing high specificity and strong cancer signal origin accuracy
• In December 2024, the Pancreatic Cancer Action Network (PanCAN) highlighted major research progress achieved in 2024, including broader use of biomarker testing and advancements in diagnostic approaches, underscoring the growing momentum in the field
• In February 2025, Oregon Health & Science University introduced PAC-MANN, a novel blood test that detected early-stage pancreatic cancer with about 85% accuracy, with results published in Science Translational Medicine, providing

SKU-69701